Claims
- 1. A method of confering an immune response to a tumor cell in a mammal, comprising administering to said mammal an antibody which binds to aspartyl (asparaginyl) beta hydroxylase (HAAH).
- 2. The method of claim 1, wherein said tumor cell is a brain tumor cell.
- 3. The method of claim 2, wherein said brain tumor cell is selected from the group consisting of a glioma, a glioblastoma, an astrocytoma, and a hemangioma.
- 4. The method of claim 1, wherein said tumor cell is a pancreatic carcinoma cell.
- 5. The method of claim 1, wherein said antibody binds to an extracellular domain of HAAH.
- 6. The method of claim 1, wherein said antibody binds to a catalytic domain of HAAH.
- 7. The method of claim 6, wherein said catalytic domain comprises amino acids 660-700 of SEQ ID NO:2.
- 8. The method of claim 1, wherein said antibody is FB50 or a fragment thereof.
- 9. The method of claim 1, wherein said antibody is selected from the group consisting of FB50, 86A, 5C7 and 19B.
- 10. The method of claim 1, wherein said antibody is a mixture of one or more antibodies selected from the group consisting of FB50, 86A, 5C7 and 19B.
- 11. The method of claim 1, wherein said antibody is a high affinity single chain antibody.
- 12. A method of inhibiting tumor growth in a mammal, comprising administering to said mammal an HAAH-binding antibody conjugated to a cytotoxic agent.
- 13. A method of inducing an HAAH-specific immune response in a mammal, comprising administering to said mammal an HAAH polypeptide.
- 14. The method of claim 13, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:2.
- 15. The method of claim 13, wherein said polypeptide comprises an extracellular domain of HAAH and lacks an intracellular domain of HAAH.
- 16. The method of claim 13, wherein said polypeptide comprises a catalytic domain of HAAH.
- 17. The method of claim 16, wherein said polypeptide comprises amino acids 650- 700 of SEQ ID NO:2.
- 18. The method of claim 13, further comprising administering an adjuvant composition.
- 19. A method of inducing an HAAH-specific immune response in a mammal, comprising administering to said mammal a polynucleotide composition encoding an HAAH polypeptide, or a degenerate variant of said polynucleotide.
- 20. The method of claim 19, wherein said composition comprises a transfection- enhancing agent.
- 21. The method of claim 19, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO:2.
- 22. The method of claim 19, wherein said polypeptide comprises an extracellular domain of HAAH and lacks an intracellular domain of HAAH.
- 23. The method of claim 19, wherein said polypeptide comprises a catalytic domain of HAAH.
- 24. The method of claim 23, wherein said polypeptide comprises amino acids 650- 700 of SEQ ID NO:2.
- 25. A method for diagnosing a neoplasm in a mammal, comprising contacting a tissue of said mammal with a detectably-labeled antibody which binds to HAAH, wherein an increase in the level of antibody binding at a tissue site compared to the level of binding to a normal nonneoplastic tissue indicates the presence of a neoplasm at said tissue site.
- 26. The method of claim 25, wherein said antibody is labeled with a radioactive compound.
- 27. The method of claim 26, wherein said radioactive compound is selected from the group consisting of 125I, 99Tc.
- 28. The method of claim 25, wherein said antibody is labeled with Gd+or Fe++.
- 29. The method of claim 25, wherein said antibody is labeled with a colorimetric agent.
- 30. The method of claim 25, wherein said tissue is a lymphoid tissue.
- 31. A fragment of HAAH comprising an extracellular domain and lacking a cytoplasmic domain of said HAAH.
- 32. A fragment of HAAH, wherein said fragment lacks residues 660-758 of SEQ ID NO:2.
- 33. A fragment of HAAH, wherein said fragment lacks residues 679-697 of SEQ ID NO:2.
- 34. A fragment of HAAH, wherein said fragment lacks at least one residue of SEQ ID NO:2, wherein said residue is selected from the group consisting of residue 661, 662, 663, 670, 671, 672, and 673.
- 35. An antibody or fragment thereof, which binds to HAAH, wherein said antibody is selected from the group consisting of FB50, 86A, 5C7 and 19B.
- 36. An antibody or HAAH-binding fragment thereof, wherein said antibody binds to a polypeptide comprising the amino acid sequence of NPVEDS (residues 286-291 of SEQ ID NO:2).
- 37. An antibody or HAAH-binding fragment thereof, wherein said antibody binds to a polypeptide comprising the amino acid sequence of QPWWPK (residues 573-579 of SEQ ID NO:2).
- 38. An antibody or HAAH-binding fragment thereof, wherein said antibody binds to a polypeptide comprising the amino acid sequence of LPEDENLR (residues 613-620 of SEQ ID NO:2).
- 39. A kit for detecting a tumor cell, comprising an antibody, or fragment thereof, which binds to HAAH.
- 40. The kit of claim 39, further comprising a means for detecting binding of said antibody to said tumor cell.
- 41. The kit of claim 40, wherein said means is a detectable marker.
- 42. The kit of claim 41, wherein said detectable marker is a radioactive compound.
- 43. The kit of claim 41, wherein said detectable marker is Gd.. or Fe++
- 44. A hybridoma cell line selected from the group consisting of hybridoma FB501, hybridoma HA386A, hybridoma HA15C7A, and hybridoma HA219B.
- 45. A fragment of HAAH, wherein said fragment lacks enzymatic activity.
- 46. A fragment of HAAH, wherein said fragment lacks an alpha-ketoglutarate binding domain and an EGF-like domain.
Parent Case Info
[0001] This application claims priority to patent application U.S. Ser. No. 09/436,184, filed on Nov. 8, 1999, the contents of which are hereby incorporated by reference.
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with U.S. Government support under National Institutes of Health grants CA-35711, AA-02666, AA-02169, and AA11431. The government has certain rights in the invention.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09436184 |
Nov 1999 |
US |
Child |
09859604 |
May 2001 |
US |